Mostrar el registro sencillo del ítem

Resistance acquisition after seven cycles of in vitro bleomycin exposure

dc.contributor.authorBurgos-Molina, Antonio Manuel 
dc.contributor.authorGil-Carmona, Luisa
dc.contributor.authorLumbreras-Vega, Luis Joaquín 
dc.contributor.authorRuiz-Gómez, Miguel José 
dc.date.accessioned2019-01-16T11:58:35Z
dc.date.available2019-01-16T11:58:35Z
dc.date.created2018
dc.date.issued2019-01-16
dc.identifier.urihttps://hdl.handle.net/10630/17157
dc.description.abstractBleomycin is an antineoplastic drug that causes DNA damage by intra- and inter-strand crosslink and DNA strand breaks. This drug is used to treat several types of cancer. The aim of this work is to study the effect of Bleomycin on S. cerevisiae cells and select bleomycin-resistant cells to study the process of resistance acquisition to establish new protocols in in vitro drugs exposure.en_US
dc.description.sponsorshipUniversidad de Málaga. Campus de Excelencia Internacional Andalucía Tech.en_US
dc.language.isoengen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMedicinaen_US
dc.subject.otherBleomycinen_US
dc.subject.otherAntineoplastic drugsen_US
dc.titleResistance acquisition after seven cycles of in vitro bleomycin exposureen_US
dc.typeinfo:eu-repo/semantics/conferenceObjecten_US
dc.centroFacultad de Medicinaen_US
dc.relation.eventtitle16th ASEICA International Congress 2018en_US
dc.relation.eventplaceValencia (España)en_US
dc.relation.eventdate06-08/11/2018en_US
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*


Ficheros en el ítem

Nombre:
2.- Resistance acquisition after ...
Tamaño:
369.1Kb
Formato:
PDF

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional